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Context: Quality of life (QoL) has been variously reported as normal or impaired in adults with
congenital adrenal hyperplasia (CAH). To explore the reasons for this discrepancy we investigated
the relationship between QoL, glucocorticoid treatment and other health outcomes in CAH adults.
Methods: Cross-sectional analysis of 151 adults with 21-hydroxylase deficiency aged 18–69 years in
whom QoL (assessed using the Short Form Health Survey), glucocorticoid regimen, anthropometric
and metabolic measures were recorded. Relationships were examined between QoL, type of
glucocorticoid (hydrocortisone, prednisolone and dexamethasone) and dose of glucocorticoid
expressed as prednisolone dose equivalent (PreDEq). QoL was expressed as z-scores calculated from
matched controls (14 430 subjects from UK population). Principal components analysis (PCA) was
undertaken to identify clusters of associated clinical and biochemical features and the principal
component (PC) scores used in regression analysis as predictor of QoL.
Results: QoL scores were associated with type of glucocorticoid treatment for vitality (PZ0.002) and
mental health (PZ0.011), with higher z-scores indicating better QoL in patients on hydrocortisone
monotherapy (P!0.05). QoL did not relate to PreDEq or mutation severity. PCA identified three PCs
(PC1, disease control; PC2, adiposity and insulin resistance and PC3, blood pressure and mutations)
that explained 61% of the variance in observed variables. Stepwise multiple regression analysis
demonstrated that PC2, reflecting adiposity and insulin resistance (waist circumference, serum
triglycerides, homeostasis model assessment of insulin resistance and HDL-cholesterol), related to QoL
scores, specifically impaired physical functioning, bodily pain, general health, Physical Component
Summary Score (P!0.001) and vitality (PZ0.002).
Conclusions: Increased adiposity, insulin resistance and use of prednisolone or dexamethasone are
associated with impaired QoL in adults with CAH. Intervention trials are required to establish whether
choice of glucocorticoid treatment and/or weight loss can improve QoL in CAH adults.
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Health-related quality of life (QoL) in adult patients with
congenital adrenal hyperplasia (CAH) has been var-
iously reported. Three groups have reported better,
similar or mildly impaired QoL in CAH patientsne.orgcompared with controls or the normal population
(1, 2, 3), while another three publications have reported
poor QoL in CAH adults (4, 5, 6). The reason for this
heterogeneity in QoL reporting for CAH adults is
unclear but could relate to variables including treat-
ment regimen, health care provision in differentThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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QoL in a large cohort of UK adult patients with CAH (7).
In this cohort we found that increasing glucocorticoid
dose was associated with poor disease control and that
dexamethasone treatment was associated with increa-
sed insulin resistance (8), but health outcomes were not
associated with genotype (9). Overall, despite a large
variety of glucocorticoid treatment regimens, androgen
levels were generally poorly controlled and this was
associated with an adverse metabolic profile including
obesity. Similar observations of poor disease control,
obesity and poor metabolic outcome have recently been
reported in a large cohort of American CAH patients of
whom 74 were adults (10). It is well established that
obesity in the general adult population is related to a
host of morbidities including impaired QoL (11, 12).
Here, we have studied the relationship between QoL,
glucocorticoid treatment regimen, disease control, and
health measures including adiposity to better define the
factors that associate with QoL in CAH adults.Materials and methods
Patients
The UK Congenital adrenal Hyperplasia Adult Study
Executive (CaHASE) cohort is a cross-sectional study of
adult CAH patients, 18 years or older, recruited from
17 specialised British endocrinology centres. The study
protocol was approved by West Midlands MREC
(MREC/03/7/086) and registered with ClinicalTrials.
gov (NCT00749593) (7). All participants gave written
informed consent. One hundred and fifty-one subjects,
all of whom were 21-hydroxylase deficient (50 males,
47 with classic and three with non-classic CAH; 101
females, 75 with classic and 26 with non-classic CAH),
completed QoL questionnaires.Treatment
Treatment with hydrocortisone (nZ41, 21 males and
20 females), prednisolone (nZ65, 17 males and 48
females), hydrocortisone and prednisolone combination
(nZ8, one male and seven females) and any treatment
regimen with dexamethasone (nZ34, 11 males and 23
females) were included. The median duration of specific
treatments was 10 years for hydrocortisone, 6.0 years
for prednisolone, 1.0 year for hydrocortisone and
prednisolone combination and 2.2 years for any
treatment regimen with dexamethasone. For the
purpose of some analyses treatment dose was converted
to prednisolone dose equivalent (PreDEq) using the
British National Formulary formula for comparing
potency of glucocorticoids (13). This gives a ratio of
prednisolone:hydrocortisone:dexamethasone of 1:4:0.15.
PreDEq were grouped into the following categories for
analysis:!5, 5–7.4,R7.5 mg.www.eje-online.orgQuality of life
QoL was assessed by Short Form Health Survey (SF-36)
using self-administered questionnaires. The SF-36
comprises health concepts measuring functioning (the
ability to perform daily tasks and activities) and well-
being (subjective internal states) of the subjects,
including how people feel physically and emotionally
and how they think and feel about their health. There
are eight domains: physical functioning, role function-
ing limitations due to poor physical health, bodily pain,
general health, vitality, social functioning, role func-
tioning limitations due to poor emotional health and
mental health. The first four domains were also grouped
into Physical and the latter four domains grouped into
Mental Component Summary Scores, derived from
principal components analysis (PCA) of the SF-36 as
previously described (14). Reference data for SF-36
scores were obtained from Prof. John Brazier (University
of Sheffield, UK) comprising a representative random
sample of 14 430 subjects from the UK population aged
18–79 years. For every CAH patient, 20 sex- and age-
matched controls were randomly selected from the
respective reference samples and z-scores generated.
Adjustment for age and sex was performed by
transformation of all domain score values from patients
into age- (decade) and sex-adjusted z-scores.Health outcomes
Health outcomes included systolic blood pressure (SBP)
and diastolic blood pressure (DBP), height, weight, waist
circumference, biochemical assessment for fasting plasma
glucose, serum insulin, total and HDL cholesterol and
triglycerides, and steroid hormones including 17-hydroxy-
progesterone (17-OHP), androstenedione and testoster-
one. All laboratories participate in the UK NEQAS scheme
for quality control of biochemical assays. Patients were
categorised into established mutation groups according to
their genotype with the less severe mutation determining
the group (9). Insulin resistance was calculated from the
homeostasis model assessment of insulin resistance
(HOMA-IR): insulin resistanceZ(fasting insulin
(units/ml)!fasting glucose (mmol/l)/22.5).Statistical analysis
We looked at the relationship between QoL and other
parameters using two different statistical methods:
ANOVA with post-hoc analysis by least significant
difference and PCA. ANOVA was used to investigate diff-
erences between groups, for example, those using
different glucocorticoid treatment regimens. PCA was
employed to reduce data by extracting only the
important combinations of interrelated variables
(principal components (PCs)) that account for a
maximal amount of variance for a range of observed
variables without losing much information from the
Table 1 QoL SF-36 standardised scores and z-scores for CAH
adults, based on reference data obtained from Prof. John Brazier
(University of Sheffield, UK) comprising a representative random
sample of 14 430 subjects from the UK population aged 18–79
years. For every CAH patient, 20 sex- and age-matched controls
were randomly selected from the respective reference samples and
z-scores generated. Adjustment for age and sex was done by
transforming all domain score values from patients into age-
(decade) and sex-adjusted z-scores.
Standardised
scores
(meanGS.D.)
Z-scores
(meanGS.D.)
Physical function 81.2G25.2 K0.74G1.53
Role limitations due to
physical problems
74.2G37.7 K0.71G1.33
Bodily pain 68.4G27.8 K0.45G1.26
General health 56.1G25.4 K0.61G1.09
Vitality 50.4G21.6 K0.87G1.21
Social functioning 73.2G26.9 K0.54G1.02
Role limitations due
to emotional problems
69.3G40.1 K0.91G1.66
Mental health 65.9G20.9 K0.72G1.19
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so that the first one (PC1) captures the largest possible
amount of variation in the original data. The respective
component scores derived from the PCs may be used for
further analysis as predictor variables in regression
analysis against dependent variables such as used in our
analysis: domains of QoL. PCA using 1.0 s as prior
communality estimates (a communality refers to sum of
squared loadings across variables) and the principal axis
method was used to extract the components followed by
a varimax (orthogonal) rotation. Components were
retained for rotation if they fulfilled the Kaiser criterion
(eigenvaluesO1; indicating thatO10% of the variance
(r2) is extracted by a given component) (16) and scree
test (17). In rotated component pattern, a variable was
selected for a given PC if the factor loading wasR0.50
for that PC, and !0.50 for the other. At least three
variables that displayed a common construct were
required to load on each PC. In this study PCA was
carried out for ten variables of metabolic and disease
control measures and mutation severity to derive three
PCs (PC1, PC2 and PC3). The three PCs were used as
predictor variables in stepwise multiple regression
analysis against the dependent variables: age- and sex-
adjusted z-scores for each of the eight domains of QoL
and each of the Component Summary Scores. Results
were presented as F statistic with 3 and 148 degrees of
freedom between and within samples respectively for
ANOVA and regression coefficients (b) and 95% CI for
regression analysis. Analyses were performed using
SPSS version 19.0 (SPSS, Inc.). Statistical significance
was assumed when P!0.05.Results
Standardised scores and z-scores for the eight domains of
QoL are presented in Table 1. Analysis of these domains
between patients taking different types of glucocorticoid
demonstrated a difference for vitality (ANOVA: FZ5.1,
PZ0.002) and mental health (ANOVA: FZ3.9,
PZ0.011). Post-hoc analysis revealed that compared
with hydrocortisone monotherapy patients, vitality and
mental health z-scores were lower in those taking
combined hydrocortisone plus prednisolone therapy
(P!0.01), prednisolone (P!0.01, for vitality only),
and any regimen with dexamethasone (P!0.05)
(Fig. 1). QoL did not correlate with PreDEq categories,
mutation severity or classic vs non-classic phenotypes.
We then carried out a detailed PCA and extracted
three PCs (PC1, PC2 and PC3) with observed eigen-
values ofO1 that explained 61% of the total variance in
the observed variables, with Kaiser-Meyer-Olkin
measure of sampling adequacy (0.66) and Bartlett’s
test of sphericity (c2Z170, P!0.001). PC1 reflects
‘disease control’ comprising androstenedione, 17-OHP
and testosterone. PC2 reflects ‘adiposity and insulin
resistance’ comprising waist circumference, serumtriglycerides, HOMA-IR and HDL-cholesterol. PC3
reflects ‘blood pressure and mutations’ comprising
SBP, DBP and mutations.
The resulting PC scores obtained from PCA were
analyzed by stepwise multiple regression analysis
(adjusted for PreDEq and glucocorticoid regimens) to
assess their relationship with each of the eight domains
of QoL z-scores and each of the two Component
Summary Scores. PC1 ‘disease control’ and PC3 ‘blood
pressure and mutations’ did not associate with any of
the QoL domains. By contrast, PC2, reflecting ‘obesity
and insulin resistance’, related to impaired physical
functioning (bZK0.72, 95% CI: K1.11 to K0.35,
r2Z19.9%, P!0.001), bodily pain (bZK0.55, 95% CI:
K0.82 to K0.28, r2Z21.6%, P!0.001), general
health (bZK0.50, 95% CI: K0.80 to K0.20,
r2Z16.0%, PZ0.001), vitality (bZK0.40, 95% CI:
K0.65 to K0.16, r2Z15.5%, PZ0.002) and Physical
Component Summary Score (bZK0.58, 95% CI:
K0.83 to K0.33, r2Z26.4%, P!0.001) (Table 2).
This relationship has not influenced PreDEq, type of
glucocorticoid replacement (hydrocortisone, predniso-
lone and dexamethasone) and their respective doses
and treatment regimens (dosage frequency: once daily,
twice daily, thrice daily and timing of administration:
circadian patterns). Figures 2 and 3 show the compo-
nents of PC2, reflecting ‘obesity and insulin resistance’,
plotted against the scores for physical functioning and
vitality that illustrates the observed poorer health
outcome measures in patients with lower QoL z-scores.Discussion
We found QoL to be worse in adult CAH patients using
prednisolone and dexamethasone compared with those
only taking hydrocortisone. We also found that markerswww.eje-online.org
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Figure 1 Association between type of glucocorticoid and QoL.
Boxplots representing median and interquartile ranges of QoL
(SF-36) z-scores of the two QoL domains, vitality (A) and mental
health (B), for CAH patients using different type of glucocorticoid
treatment; whiskers represent the 5th and 95th percentiles.
A z-score of 0 represents the median of the reference population.
Post-hoc analysis: compared with hydrocortisone-treated patients,
z-scores for vitality and mental health were lower in those treated
with a combination of hydrocortisone plus prednisolone (**P!0.01),
any dexamethasone combination (*P!0.05) or prednisolone
(**P!0.01, for vitality only). HC, hydrocortisone; Pred, predniso-
lone; Dex, dexamethasone.
Table 2 Regression coefficients (b) and explained variances (r2)
obtained from stepwise multiple regression analysis using the three
principal components (PC1, PC2 and PC3) as predictor variables
and health-related QoL SF-36 questionnaire age- and sex-adjusted
z-scores as dependent variables. Only PC2, reflecting adiposity and
insulin resistance (waist circumference, serum triglycerides,
HOMA-IR and HDL-cholesterol), was retained showing adverse
relationships with physical function, bodily pain, general health,
vitality and Physical Component Summary Score. Additional
adjustment for PreDEq or type of glucocorticoid replacement
(hydrocortisone, prednisolone and dexamethasone) did not change
these relationships.
Predictor variable (PC2, adiposity and
insulin resistance)
Dependent variables b (95% CI) P r2 (%)
Physical function K0.72 (K1.11 toK0.35) !0.001 19.9
Role limitations due
to physical problems
NS – –
Bodily pain K0.55 (K0.82 toK0.28) !0.001 21.6
General health K0.50 (K0.80 toK0.20) 0.001 16.0
Physical Component
Summary Scorea
K0.58 (K0.83 toK0.33) !0.001 26.4
Vitality K0.40 (K0.65 toK0.16) 0.002 15.5
Social functioning NS – –
Role limitations due
to emotional problems
NS – –
Mental health NS – –
Mental Component
Summary Scoreb
NS – –
NS, Not significant.
aPhysical Component Summary Score comprises four of the eight QoL
domains: physical functioning, role functioning limitations due to poor
physical problems, bodily pain and general health.
bMental Component Summary Score comprises the other four QoL domains:
vitality, social functioning, role functioning limitations due to poor emotional
health and mental health.
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serum triglycerides, HOMA-IR and HDL-cholesterol)
were associated with a worse QoL. Combining these QoL
data with our previous analysis of metabolic parameters
(8) in this cohort of UK patients suggests that treatment
with more potent glucocorticoids or combination
therapy is associated with a poor metabolic profile and
impaired QoL. It is not possible to infer from our results
what is cause or effect. Patients who have poor disease
control and impaired QoL may be those that are selected
for more potent glucocorticoids, or the treatment itself
may reduce QoL.www.eje-online.orgOur study is the largest published cohort of CAH
adults and the first to report on the relationship between
QoL, glucocorticoid treatment and health outcomes.
Our QoL results are at variance with some previous
reports. In a nationwide Finnish study, 108 CAH
patients were identified; these, 58 were over 16 years,
and 32 completed a QoL questionnaire (RAND-36) (1).
In this subgroup of patients QoL was significantly better
than the reference Finnish population and commenta-
tors speculated this was because of greater physician–
patient contact. In a study of 81 German CAH patients
from two tertiary care centres the patients had impaired
health-related QoL in three of five GBB-24 scores
whereas SF-36 and Hospital Anxiety and Depression
Scores (HADS) did not differ from controls, and QoL was
significantly better than a comparator group of patients
with primary adrenal insufficiency (2). As both adrenal
insufficiency and CAH patient groups receive glucocor-
ticoids the authors suggested that factors other than
hormone replacement therapy could account for the
difference in QoL. One factor they discuss is that patients
with a congenital disease may have a different
perception of QoL to those with an acquired condition.
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Figure 2 Association between individual components of the
adiposity and insulin resistance (PC2) and physical functioning
QoL. Error plots with mean and 95% confidence limits showing
the size of waist circumference (A), levels of triglycerides (B),
HDL cholesterol (C) and HOMA-IR (D) according to the physical
functioning domain categorised into three groups based on
z-scoresR0 (nZ69),!0 toK1 (nZ36) and!K1 (nZ46).
Post-hoc analysis: **P!0.01, ***P!0.001 compared with group
with z-scoreR0.
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clinic, QoL (EDLQ) in 45 adult female CAH patients was
similar to control subjects who were staff at the same
hospital (3). The authors considered that differences
found regarding social support and illness processing
may be mechanisms patients have developed to help
them to cope with their condition. In contrast to these
three reports, our results showed that QoL of CAH
adults is impaired in comparison with QoL in the
general population and that impaired QoL is related to
type of glucocorticoid treatment. One potential reason
for the difference in results is that our cohort of patients
was managed in 17 different centres, using a variety of
treatment regimens and with a great spectrum of
disease control. Some patients appeared over-treated,
based on suppressed androgens, and some patients
under-treated, based on raised androgens. In contrast,
the previously reported studies either come from a
selected subgroup of patients or from single centres
where patients were treated by a relatively small
number of clinicians, who may have obtained tighter
control of their disease. However, our findings of
impaired QoL in adults with CAH are consistent with
some other studies. In a cross-sectional study of 104
Norwegian patients, QoL was impaired in all the SF-36
subdomains and most pronounced for general health
and vitality perception (5). In this cohort, working
disability was reported by 19% of the patients,
compared with 10% in the general population.
We found that QoL in adults with CAH related to
adiposity and insulin resistance. This has not been
reported previously, but is recognised in the general
population where QoL, as measured by SF-36, is
impaired in people with increased adiposity (11, 12)
and insulin resistance (18). We observed that increased
adiposity, and its consequent insulin resistance, relates
to the three ‘physical’ QoL domains of the SF-36
(physical functioning, bodily pain and general health)
but only to the vitality domain of the ‘mental health’
criteria. This distinction was further confirmed in our
analysis where adiposity and insulin resistance were
inversely related to the Physical Component Summary
Score but not the Mental Component Summary Score of
SF-36. The results are consistent with the observation
that increased adiposity and insulin resistance in
European populations relate primarily to adverse
physical health rather than mental health criteria of
QoL (11, 12, 18). In PCA analysis of SF-36, although
the vitality domain was retained by the Mental
Component Summary Score, its loading (correlation,
rZ0.654) on this component is not as strong as the
other three domains (social functioning, role function-
ing limitations due to poor emotional health and mental
health: rR0.825). In fact, the vitality domain also loads
on the Physical Component Summary Score but with
less weight (correlation, rZ0.515). This finding is
similar to previous published results obtained from a
general USA population sample showing vitality towww.eje-online.org
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Figure 3 Association between individual components of the
adiposity and insulin resistance (PC2) and vitality QoL. Error plots
with mean and 95% confidence limits showing the size of waist
circumference (A), levels of triglycerides (B), HDL cholesterol
(C) and HOMA-IR (D) according to the vitality domain categorised
into three groups based on z-scoresR0 (nZ69),!0 toK1 (nZ36)
and !K1 (nZ46). Post-hoc analysis: *P!0.05, **P!0.01
compared with group with z-scoreR0.
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Component Summary Scores (0.47) (14). The two
Component Summary Scores therefore are not
exclusively independent and should be interpreted
with the individual QoL domains as we have done in
our analysis (14, 19).
QoL did not relate to genotype (mutations) (9) or
phenotype (classic or non-classic) (7). This observation
supports the concept that the impaired QoL is acquired
and may in part relate to type of glucocorticoid treatment
(i.e. adverse effects from prednisolone or dexamethasone)
or reflect the patients’ poor disease control.
Limitations in this study include its cross-sectional
nature and the large number of variables examined. It is
difficult to quantify the absolute exposure and duration
of specific glucocorticoid regimens. It is likely that most
patients were treated with hydrocortisone during child-
hood (20). The duration of glucocorticoid treatment was
recorded with the median for each type of treatment
ranging between 1 and 10 years. To address the large
number of variables within this database, PCA was
employed as it allowed us to examine associations in
large and complex multivariate databases that requires
no a priori assumptions about the data and is thus ideal
for exploratory data analysis (15). Future prospective
studies designed specifically to examine the long-term
effects of glucocorticoid therapy in CAH patients are
needed to address the limitations of this study.
In conclusion, increased adiposity, insulin resistance
and the use of combination glucocorticoid therapy with
prednisolone and dexamethasone are associated withwww.eje-online.orgimpaired QoL in adults with CAH independently of
mutation severity. However, whether obesity or treat-
ment results in poor QoL or vice versa is yet to be
established. Further studies, ideally randomised con-
trolled intervention trials, are required to establish
whether choice of glucocorticoid treatment and/or
weight loss can improve QoL in CAH adults.Declaration of interest
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